NCT04439045View on ClinicalTrials.gov

Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity

PHASE3CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

June 24, 2020

Primary Completion Date

September 9, 2021

Study Completion Date

September 9, 2021

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

VPM1002

VPM1002 is a recombinant BCG (rBCG)

OTHER

Placebo

0.9% sodium chloride

Trial Locations (1)

M5G 2M9

University Health Network, Toronto

All Listed Sponsors
collaborator

Serum Institute of India Pvt. Ltd.

INDUSTRY

collaborator

Max Planck Institute for Infection Biology

OTHER

collaborator

Verity Pharmaceuticals Inc.

INDUSTRY

lead

University Health Network, Toronto

OTHER

NCT04439045 - Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity | Biotech Hunter | Biotech Hunter